Shilpa Biologicals, a Shilpa Medicare subsidiary, signed a licensing deal with SteinCares to commercialise a biosimilar in Latin America. SteinCares gets exclusive rights, while Shilpa handles development and manufacturing, marking its Latin American market entry.
